BINEX (053030) Fundamentals 2026 — Revenue Analysis | SniperIQ
BINEX (053030) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩202.2B, trading at ₩6350.00 on the KOE. This SniperIQ fundamentals page covers BINEX's valuation, profitability (net margin -7.8%), revenue (₩168.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BINEX's market cap?
BINEX (053030) has a market capitalization of approximately ₩202.2B, trading at ₩6350.00 on the KOE. Market cap moves with the live share price.
What is BINEX's P/E ratio?
BINEX's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is BINEX?
BINEX runs a net profit margin of -7.8%, a gross margin of 22.3%, and an operating margin of -8.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does BINEX generate?
BINEX reported revenue of ₩168.5B for fiscal year 2025, with net income of -₩3.2B and earnings per share (EPS) of -101. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does BINEX pay a dividend?
BINEX does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is BINEX financially healthy?
BINEX carries a debt-to-equity ratio of 0.59x and a current ratio of 1.50x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is BINEX a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BINEX (053030) the key facts are: market cap ₩202.2B, revenue ₩168.5B, 52-week range 6320-19200. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track BINEX's full fundamentals live
Get BINEX's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.